Overview
The evidence base for CJC-1295 with DAC can span preclinical work, early human data, and—where applicable—larger clinical trials. The strength and maturity of that evidence determine how confidently clinicians and researchers talk about its effects.
Key evidence themes
- Preclinical models exploring mechanisms and proof-of-concept.
- Early human or pilot data, if available.
- Larger controlled trials for molecules with formal indications.
Context and caveats
When reviewing literature on CJC-1295 with DAC, it is important to consider study design, endpoints, sample size, and duration, as well as how closely study populations match real-world use. Marketing narratives frequently move faster than rigorous evidence.
Sport & Anti-Doping Warning
CJC-1295 (a GHRH analogue) has been documented in team-sport doping programs, often paired with GHRP-type secretagogues to boost growth hormone and IGF-1.
- >Cronulla-Sutherland Sharks supplements saga (CJC-1295 and GHRP-6 in NRL)
- >Overview of growth hormone–related peptides on the WADA Prohibited List
Long-acting GH-axis peptides like CJC-1295 are prohibited for WADA-code athletes and have featured in multi-player doping investigations in professional rugby league.